Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Summary

Check out this new webinar hosted by BioInsight and featured by experts in transfection working at Polyplus-transfection®, Audentes Therapeutic, Pall Life Sciences & Paragon Bioservices. This webinar on "Optimizing process development to simplify manufacturing scale up of therapeutic viral vectors" is followed by a Question & Answer Session.

Several topics are covered around the optimization of manufacturing scale-up of therapeutic viral vectors to support advanced clinical trials and commercialization.

Webinar on process development to manufacturing scale-up of therapeutic viral vectors

Please accept cookies to access this content

 

PEIpro® Product Range   Contact us for more information

0:19 Introduction to the webinar
2:10 Presentation of Polyplus-transfection
2:57 Transfection product lines
3:56 Viral Vectors Manufacturing Roadmap
6:59 Current Upstream Manufacturing Challenges
8:15 Optimized PEI for Viral Vector Production: PEIpro® product range
12:02 Scaling-up systems: adherent and suspension
14:00 Scalable transient transfection: cell culture medium
18:35 Production scale-up
21:20 PEIpro® product range: from PD with PEIpro® to commercialization with PEIpro®-GMP

Q&A Session

24:40 Experiences of viral vector manufacturing and specific pain points in scaling-up
29:45 Adherent VS suspension
36:30 Transfection efficiency factors, which criteria need to be monitored in a dynamic process?
42:50 Importance of supplier relationships as you move to commercial scale?
49:30 Could regulatory agencies ask for a QC on residual presence of PEIpro® within the final product?
50:17 Is Metabolomic used to understand the bioprocess system and how efficient transfection is?
52:55 What further improvements to look for in viral vector manufacturing process?